Glucose Injection (Baxter)

País: Nova Zelanda

Idioma: anglès

Font: Medsafe (Medicines Safety Authority)

ingredients actius:

Glucose monohydrate 10%

Disponible des:

Baxter Healthcare Ltd

Designació comuna internacional (DCI):

Glucose monohydrate 10%

Dosis:

10 %

formulario farmacéutico:

Solution for infusion

Composición:

Active: Glucose monohydrate 10%

Unidades en paquete:

Bag, 500 mL

clase:

General sale

tipo de receta:

General sale

Fabricat per:

Baxter Healthcare Corporation

indicaciones terapéuticas:

Hypertonic infusion solutions are indicated: - As a source of energy incorporated with parenteral nutrition with minimal dilution effect - For use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) The alimentary tract cannot or should not be used b) Gastrointestinal absorption of protein is impaired c) Metabolic requirements for protein are substantially increased, as with extensive burns.

Resumen del producto:

Package - Contents - Shelf Life: Bag, - 500 mL - 24 months from date of manufacture stored at or below 30°C - Bag, - 1000 mL - 24 months from date of manufacture stored at or below 30°C

Data d'autorització:

1977-09-06

Fitxa tècnica

NEW ZEALAND DATA SHEET
Glucose (Viaflex) Data Sheet 26 September 2019
Page 1 of 14
Baxter Healthcare Ltd
1 GLUCOSE INJECTION (BAXTER), (solution for infusion)
GLUCOSE Injection (Baxter)
5% solution for infusion
Glucose Injection (Baxter)
10% solution for infusion
Glucose Injection (Baxter)
25% solution for infusion
Glucose Injection (Baxter)
50% solution for infusion
Glucose Injection (Baxter)
70% solution for infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
_Active ingredient _
The active ingredient is glucose (monohydrate).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for infusion.
Glucose Injection (Baxter) are clear slightly coloured solutions for
intravenous (IV) infusion, in a
Viaflex® plastic bag.
The Glucose Injection (Baxter) infusion preparations are sterile,
non‐pyrogenic parenteral solutions.
They do not contain an antimicrobial agent or added buffer, and have a
pH of 3.5 ‐ 6.5 for 5% to 25%
glucose
concentrations,
and
a
pH
of
3.2
–
6.5
for
50%
to
70%
glucose
concentrations.
The
concentrations of glucose dissolved in a litre of Water for Injections
and their isotonicity are shown in
Tables 1 and 2 (see section 6.5).
The Glucose Injection (Baxter) 5% infusion is an _isotonic_ solution,
whereas Glucose Injection (Baxter)

10% infusions are _hypertonic_.
4 CLINICAL PARTICULARS
4.1
Therapeutic indications
Isotonic (Glucose Injection (Baxter) 5%) infusion solutions are mainly
indicated:

Whenever non‐electrolyte fluid replacement is required

As a vehicle for drug delivery, provided that the added components are
compatible with glucose.
Hypertonic (Glucose Injection (Baxter)

10%) infusion solutions are indicated:

As a source of energy incorporated with parenteral nutrition with
minimal dilution effect

For use with an appropriate protein (nitrogen) source in the
prevention of nitrogen loss or in the
treatment of negative nitrogen balance in patients where:
a)
the alimentary tract cannot or should not be used
b)
gastrointestinal absorption